NeOnc Receives FDA Written Feedback On NEO212 Development And Capsule-to-Tablet Transition

NeOnc Technologies said it received written feedback from the U.S. FDA on the CMC (chemistry, manufacturing and controls) program for NEO212. The update is process-related with no disclosed approval outcome, so the likely near-term impact appears limited absent details on any required changes.

Analysis

NeOnc Technologies said it received written feedback from the U.S. FDA on the CMC (chemistry, manufacturing and controls) program for NEO212. The update is process-related with no disclosed approval outcome, so the likely near-term impact appears limited absent details on any required changes.